| Oct 16, 2025 | Veradermics | $150.0M Series C | Katarina Pance | abrdn, Infinitium, Invus, Longitude Capital, Marshall Wace, Surveyor Capital, Suvretta Capital Management, Viking Global Investors |
| May 7, 2024 | Averto Medical | $30.0M Series A | Bihua Chen | CVF, Venrock |
| Feb 13, 2024 | ProfoundBio | $112.0M Series B | Andrew Lam | Janus Henderson Investors, Josh Jin, Logos Capital, LYFE Capital, Medicxi, Nextech Invest, Octagon Capital, OrbiMed, Piper Heartland Healthcare Capital, RA Capital Management, Surveyor Capital, T. Rowe Price Associates |
| May 10, 2022 | MOMA Therapeutics | $150.0M Series B | Amit Sinha, Amit Sinha | Alexandria Venture Investments, Casdin Capital, Cormorant Asset Management, Creacion Ventures, Invus, MOMA Therapeutics, Nextech Invest, Pavilion Capital, Rock Springs Capital, Section 32, Third Rock Ventures |
| Jan 1, 2022 | Ceptur Therapeutics | $75.0M Series A | Colin Walsh | venBio, Vivo Capital, Evan Cheng, Daniel Heller, Boxer Capital, Bristol Myers Squibb, Janus Henderson Investors, Perceptive Xontogeny Venture Fund |
| Nov 3, 2021 | Clade Therapeutics | $87.0M Series A | Martin Murphy | Bristol Myers Squibb, Neil White, Ryan Cinalli |
| Nov 1, 2021 | Antios Therapeutics | $75.0M Series B | EPIQ Capital Group, Craig Gordon | Domain Associates, Pontifax Venture Capital, Adage Capital Management, Aisling Capital, Altium Capital, Amzak Health, Avego Bioscience Capital, CAM Capital, Delos Capital, Granite Point Capital, GRA Venture Fund, Heartland Healthcare Capital, Lumira Ventures, RA Capital Management, Sixty Degree Capital, Soleus Capital |
| Jun 1, 2021 | RayzeBio | $110.0M Series C | Venrock | Atlas Venture, KohFounders, RA Capital, Samsara BioCapital, venBio, Versant Ventures, Acuta Capital Partners, Alexandria Venture Investments, Cormorant Asset Management, Deerfield Management, Logos Capital, OrbiMed, Perceptive Advisors, Redmile Group, TCGX, Viking Global Investors, Vivo Capital |
| Apr 1, 2021 | Antios Therapeutics | $96.0M Series B | Guy Levy | Domain Associates, Michele Park, Pontifax Venture Capital, Sanofi Ventures, Adage Capital Management, Aisling Capital, Amzak Health, CAM Capital, Delos Capital, Granite Point Capital, Lumira Ventures, RA Capital Management, Sixty Degree Capital |
| Mar 16, 2021 | Iridia | $24.0M Series B | Paul Yook | ATEM Capital, JSR Corporation, Longley Capital, North Sound Ventures, Priztker/Vlock Family Office, Tech Coast Angels, Validus Growth Investors, Steffen Hellmold |
| Mar 1, 2021 | Caribou Biosciences | $120.0M Series C | Farallon Capital Management, Santhosh Palani, PhD, CFA, Jeffrey Long-McGie | 1435 Capital Management, 6th Man Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co-op, Heavybit, Invariantes Fund, Kleiner Perkins, KRM Interests LLC, LombardStreet Ventures, Maverick Capital, Menlo Ventures, Mouro Capital, Necessary Ventures, QED Investors, Robert Bosch Venture Capital, Starbridge Venture Capital, Sterling Equity, William Guo, XStarPartners, Adam Marchick, Andy Rubin, Dylan Taylor, hugo angelmar, Ravi Grover, Richard Cooperstein, Rob Meyerson, Sri Batchu, Sung ho Choi, AbbVie Ventures, Adage Capital Management, Avego Bioscience Capital, Avidity Partners, Heritage Medical Systems, Invus, Janus Henderson Investors, Maverick Ventures, Monashee Investment Management, Point72, Pontifax, Tekla Capital Management, The Leukemia & Lymphoma Society |
| Mar 1, 2021 | Pyxis Oncology | $150.0M Series B | Christian Schetter, gotham makker | Pfizer Venture Investments, Acuta Capital Partners, Agent Capital, BVF Partners, Cormorant Asset Management, HBM Healthcare Investments, Janus Henderson Investors, Laurion Capital Management, Leaps by Bayer, Logos Capital, Longwood Fund, Perceptive Advisors, RA Capital Management, Ridgeback Capital Investments, Surveyor Capital, Tekla Capital Management |
| Feb 1, 2021 | Centessa Pharmaceuticals | $250.0M Series A | General Atlantic, Vida Ventures, Janus Henderson Investors | Atlas Venture, Boxer Capital, BVF Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Logos Capital, Samsara BioCapital, T. Rowe Price Associates, Venrock, Wellington Management |
| Jan 1, 2021 | Mana Therapeutics | $35.0M Series A | Cobro Ventures, Drew Dennison | — |
| Dec 1, 2020 | RayzeBio | $110.0M Series B | Venrock | Atlas Venture, Longwood Fund, RA Capital, Samsara BioCapital, venBio, Versant Ventures, Alexandria Venture Investments, Cormorant Asset Management, Logos Capital, OrbiMed, Redmile Group, Viking Global Investors |
| Aug 20, 2020 | Science 37 | $40.0M Other Equity | Adam Goulburn, PPD, Redmile Group | Amgen Ventures, Glynn Capital, Google Ventures, Mubadala Capital, Novartis, Sanofi Ventures, David Coman |
| Jun 4, 2020 | Athira Pharma | $85.0M Series B | Joseph Edelman | Richard Kayne, suzanne kayne, Avidity Partners, Franklin Templeton, Highside Capital Management, Janus Henderson Investors, Logos Capital, Rock Springs Capital, RTW Investments, Sahsen Ventures, Sofinnova Ventures, Surveyor Capital, Venrock, Viking Global Investors |
| Apr 1, 2020 | Erasca | $200.0M Series B | ARCH Venture Partners, Bihua Chen | Canaan Partners, SignalFire, City Hill Ventures, Colt Ventures, EDBI, Invus, Terra Magnum Capital Partners |
| May 1, 2019 | Cala Health | $50.0M Series C | — | Arboretum Ventures, Arcus Ventures, Beringea, AlleyCorp, Alumni Ventures, Ascension Ventures, Bradley Horowitz, Charlie Cheever, Fifth Wall, Healthy Ventures, Jonathan Bush, Kevin Love, Rob May, Action Potential Venture Capital, Nicole J Walker, Neil Tiwari, Google Ventures, Johnson & Johnson Innovation, Lightstone Ventures, Lux Capital, Novartis, Triventures |
| Jan 1, 2019 | Attune Pharmaceuticals | $23.0M Series B | Venrock | ARCH Venture Partners, Boxer Capital, RA Capital Management, Roderick Wong, Tang Capital |
| Dec 1, 2018 | Akero Therapeutics | $70.0M Series B | Janus Henderson Investors | Atlas Venture, Highbury Group, venBio, Apple Tree Partners, Boxer Capital, BVF Partners, Cormorant Asset Management, Redmile Group, Rock Springs Capital, Versant Ventures |
| Dec 1, 2017 | Allakos | $100.0M Series B | New Enterprise Associates | InterWest, Paul Walker, Novo Ventures, RiverVest, Roche Venture Fund, SR One, 3x5 Partners, Alta Partners, Partner Fund Management, Redmile Group, RiverVest Venture Partners, Roche, Rock Springs Capital, Samsara BioCapital |
